ArticleCancers2022

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy.

Zhen-Hua Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.